Dilek ÜLKER CAKIR, Mustafa REŞORLU, Zerrin ÖĞRETMEN, İsmail DAĞ

PSORİASİSLİ HASTALARDA SERUM VİSFATİN DÜZEYLERİ VE ALKOLİK OLMAYAN YAĞLI KARACİĞER HASTALIĞI VARLIĞININ METABOLİK SENDROM VE KOMPONENTLERİYLE İLİŞKİSİ

Amaç: Metabolik sendrom (MS) ve alkolik olmayan yağlı karaciğer hastalığı (NAYKH) psoriasisin önemlikomorbiditelerindendir. Visfatin, visseral beyaz yağ dokusundan salınan bir adipokindir. Obezite ve kronikinflamasyon gibi durumlarda düzeyleri yükselir. Çalışmamızda serum visfatin düzeyinin ve NAYKH varlığınınpsoriasis ve komorbiditileriyle olan ilişkisi araştırıldı.Yöntem: Çalışmamızda Çanakkale Onsekiz Mart Üniversitesi Tıp Fakültesi Dermatoloji polikliniğine başvuran,psoriasisi olan 80 hasta yer aldı. Hastalar MS’u olan ve olmayan olmak üzere 40’ar kişilik gruplara ayrıldı. 40kişilik kontrol grubu çalışmaya dahil edildi. Hastaların bel çevresi, basen çevresi ölçümleri alındı. Vücut kitleindeksi ve psoriasis alan şiddet indeksi değerleri hesaplandı. Karaciğer ultrasonografisi yapıldı. ELISA yöntemiyleserum visfatin düzeyleri ölçüldü.Bulgular: MS’u olmayan psoriasis hastalarıyla benzer yaş ve cinsiyetteki kontrol grubu serum visfatin düzeyleriaçısından karşılaştırıldığında, psoriasis hastalarında visfatin düzeyleri istatistiksel olarak anlamlı şekildedaha yüksekti (p

The Relation of Serum Visfatin Level and Non-Alcoholic Liver Disease with Metabolic Syndrome and Its Components.

Objective: Psoriasis is frequently associated with comorbidities including metabolic syndrome and nonalcoholic fatty liver disease. Visfatin is an adipokine secreted from adipocytes of white adipose tissue and its high concentrations is known to be in a relationship with abdominal obesity and chronic inflamation. This study investigates serum levels of visfatin in patients with psoriasis therefore we consider how psoriasis is linked to metabolic syndrome and non alcoholic fatty liver disease. Method: In this study, we evaluated 80 psoriasis patients which are requested Canakkale Onsekiz Mart University, Faculty of Medicine, Dermatology Department outpatient clinic. They divided into 2 groups as patients with metabolic syndrome and without diagnosis of metabolic syndrome. A healthy control group, 40 people are also included. The body mass index, waist and hip circumference were calculated. The score of psoriasis area severity index, grade of non alcoholic fatty liver disease. Our patients are also undergo ultrasonografic liver screening. For quantification of the visfatin, ELISA based assay was used . Results: Visfatin levels were found istatistically higher in the healthy (without metabolic syndrome) psoriasis group versus control group (p

PDF

___

Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaquepsoriasis. J Hepatol. 2009 Oct;51(4):778- 86.
Socha P, Wierzbicka A, Neuhoff-Murawska J, Wlodarek D, Podlesny J. Nonalcoholic fatty liver disease as a feature of the metabolic syndrome. Rocz Panstw Zakl Hig. 2007;58(1):129-37.
Chen CH, Huang MH, Yang JC, Nien CK, Yang CC. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol. 2006 Sep;40(8):745-52.
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003 Apr;37(4):917-23.
Genc H, Dogru T, Kara M, Tapan S, Ercin CN. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.Ann Hepatol. 2013 Jul-Aug;12(4):548-55.
Alexander RM, Romana RG, Herbert T. Pre-B Cell Colony Enhancing Factor/NAMPT/Visfatin in Inflammation and Obesity- Related Disorders. Current Pharmaceutical Design, June 2010;16,17:p.1913- 1920(8).
Dalamaga M, Papadavid E. Adipocytokines and psoriasis: Insights into mechanisms linking obesity and inflammation to psoriasis. World J Dermatol. 2013 November 2;2(4):27-31.
Wang P, Van Greevenbroek MM, Bouwman FG, Brouwers MC, Van Der Kallen CJ. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch. 2007; 6: 971-6.
Taşkesen D, Kirel B, Us T. Serum levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol. 2: 76-81.
Friebe D, Neef M, Kratzsch J, Erbs S, Dittrich K. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony(PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia. 2011 May;54(5):1200-11.
Samara A, Pfister M, Marie B, Visvikis-Siest S. Visfatin, low-grade inflammation and body mass index (BMI). Clin Endocrinol (Oxf). 2008 Oct;69(4):568-74.
Lin CC, Lai MM, Li TC, Li CI, Liu CS. Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome. Diabetes Res Clin Pract. 2009 Jul;85(1):24-9.
Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol. 2008 Feb;158(2):203-7.
Okan G, Baki AM, Yorulmaz E, Doğru-Abbasoğlu S, Vural P. Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity. J Clin Lab Anal. 2015 Apr 13.
Yan WQ, Huang YM, Yan X, Zhou YQ. Clinical significance of serum visfatin and high mobility groupbox¬ 1(HMGB1) in patients with psoriasis vulgaris. Chinese Journal of Clinicians. 2011;5:9.
Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012 Mar;132:556-62.
Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol. 2010 Feb;37(2):146-55.
Kim JH, Kim SH, Im JA, Lee DC. The relationship between visfatin and metabolic syndrome in postmenopausal women. Maturitas. 2010 Sep;67(1):67-71.
Iacobellis G, Iorio M, Napoli N, Cotesta D, Zinnamosca L. Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Invest. 2011 Jan;34(1):e12-5.
Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf). 2008 Dec;69(6):878-84.
Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest. 2007 Apr;30(4):323-6.
Kanda N, Hau CS, Tada Y, Tatsuta A, Sato S. Visfatin enhances CXCL8, CXCL10, and CCL20 production in human keratinocytes. Endocrinology. 2011 Aug;152(8):3155-64.
Ismail SA, Mohamed SA. Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. Br J Dermatol. 2012 Aug;167(2):436-9.
Bozkurt NM, Yıldırım M, Ceyhan AM, Kara Y, Vural H. Psoriasisli Hastalarda Serum Visfatin Düzeylerinin Araştırılması. Türkderm 2010; 44: 15-8.
Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005 Jan 21;307(5708):426-30.
Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol. 2008 Apr;83(4):804-16.
Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M. Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis? Exp Dermatol. 2012 Jan;21(1):43-7.
Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol. 2011 Feb;20(2):81-7.
Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010 Jan 15;314(1):1-16.
Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol. 2006 Dec;57(4):505-28.
Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf). 2006 Apr;64(4):355- 65.
İdilman İS, Karçaaltıncaba M. Karaciğer Yağlanması Tanısında ve Yağlanma Miktarının Belirlenmesinde Radyolojik Tanı Yöntemleri. Güncel Gastroenteroloji. 2014; s:112-8.
McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S17-29.
Gören B, Fen T. Metabolik Sendrom. Turkiye Klinikleri J Med Sci 2008;28:686-696.
Lakshmi S, Nath AK, Udayashankar C. Metabolic syndrome in patients with psoriasis: A comparative study. Indian Dermatol Online J. 2014 Apr;5(2):132-7.
Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006 May;23(5):469-80.
Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol. 2012 Mar;39(3):212-8.
Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014 Apr 17;7:119-32.